FDA Questions Efficacy Of Novartis Inhaled CF Treatment
U.S. Food and Drug Administration staffers have questioned whether Novartis AG's inhaled powder form of a cystic fibrosis treatment is effective enough to warrant agency approval, according to documents posted to...To view the full article, register now.
Already a subscriber? Click here to view full article